Pankreas duktal adenokarsinomunda NF-Kappa B ekspresyonu

Amaç: Bu çalışmada, NF-KB kompleksinin alt grubu olan p65 ve fosfo-IKB-alfa antikor ile NF-KB’nin aktivasyonu durumu araştırılmıştır.Gereç ve Yöntem: Doku mikroarray yöntemi ile 107 olgu üzerinden yapılan çalışmada antikorun boyanması, boyanma şiddeti ve yüzdesi beraber değerlendirilerek skorlandı. Cell Signaling Technology ürünlerinden p65 ve fosfo-IKB-alfa(ser32/36) kullanıldı. Boyanma skorlarının arşiv bilgileri doğrultusunda cerrahi sınır, lenf bezi durumu, evre, tümör boyutu ve klinik bilgiler ışığında genel yaşam süresi ile korelasyonu araştırıldı. Bulgular: P65 nükleer, p-IkB-alfa sitoplazmik boyanma paterni izledi. Karsinomda, tümör içermeyen bölgelerle kıyaslandığında boyanma belirgin oranda şiddetli olup ve NF-KB aktivitesinde artış mevcuttu. NF-kB(p65) ekspresyonu, lenf bezi durumu ile anlamlı bir korelasyon göstermekle birlikte  yaş, ırk, cinsiyet, tümör lokalizasyonu, tümör boyutu, tümör derecesi ve genel yaşam süresi ile NF-KB(p65), pIkBalfa arasında korelasyon izlenmedi.Sonuç: Lenf bezi durumu ile NF-KB aktivitesinin korelasyonu tümörün invaziv olma özelliğini ön plana çıkartmakta olup pankreas karsinogenezinde erken aşamalarda görülmesi tedavi açılımlarının geliştirilmesi açısından hedef molekül olabileceğini düşündürmektedir.
Anahtar Kelimeler:

NF-Kappa B, pankreas

NF-Kappa B expression in pancreatic ductal carcinoma

Purpose: In this study we investigated the expression of the p65 subunit of the nuclear factor-kappaB (NF-kB)  complex and  the activation status of NF-kB by phospho-IkB-alpha antibody.Materials and Methods: A tissue microarray based on material obtained from 107 patients was utilized. The antibody staining was scored by combining staining intensity with percentage of tumor staining. The antibodies used were NF-kB p65 and phospho-IkB-alpha(ser32/36), both from Cell Signaling Technology. The staining scores were correlated with the archival data available on some patients on margin and lymph node status, stage, tumor size, as well as clinical data including survival.Results: The staining was nuclear (p65) and cytoplasmic (p-IkBalpha) respectively. In general there was an increased expression and activation of NF-kB in the carcinomas, compared to non-tumoral regions. None of the markers had a significant correlation with the overall survival. NF-kB(p65) expression had a correlation with positive lymph node status.Conclusion: The correlation with the positive lymph node status suggests a role in invasive properties of the tumor. Activation of NF-kB is most likely an early event in pancreatic carcinogenesis. Despite the lack of an effect on overall survival, due to its increased activation in pancreatic cancer, NF-kB is still a good target for therapeutic interventions.

___

  • 1. Siegel R, Miller K, Jemal A. Cancer statistics 2018. CA Cancer J Clin. 2018;68:7-30.2.
  • 2. Haller D. New perspectives in the management of pancreas cancer. Semin Oncol. 2003;30:3-10.
  • 3. Hezel A, Kimmelman A, Stanger B, Bardeesy N, Depinho R. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev. 2006;20:1218-49.
  • 4. Khan M, Azim S, Zubair H, Bhardwaj A, Patel G, Khushman M et al. Molecular Drivers of Pancreatic Cancer Pathogenesis: Looking Inward to Move Forward. Int J Mol Sci. 2017;18:779.
  • 5. Ling J, Kang Y, Zhao R, Xia Q, Lee DF, Chang Z et al. KrasG12D-induced IKK2/β/NF-κB activation by IL-1α and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma. Cancer Cell. 2012;21:105-20.
  • 6. Prabhu L, Mundade R, Korc M, Loehrer P, Lu T. Critical role of NF-κB in pancreatic cancer. Oncotarget. 2014;5:22.
  • 7. Tuncel D. Role of NF-Kappa B in the Approach to Pancreatic Ductal Adenocarcinoma. Archives Medical Review Journal. 2015;24:565-77.
  • 8. Gilmore TD. Introduction to NF-kappaB: players, pathways, perspectives. Oncogene. 2006;25:6680-4.
  • 9. Verma IM, Stevenson JK, Schwarz EM, Van Antwerp D, Miyamoto S. Rel/NF-kappa B/I kappa B family: intimate tales of association and dissociation. Genes Dev. 1995;9:2723-35.
  • 10. Siebenlist U, Franzoso G, Brown K. Structure, regulation and function of NF-kappa B. Annu Rev Cell Biol, 1994;10:405-55.
  • 11. Baldwin, A.S., Jr., The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol, 1996;14:649-83.
  • 12. Ghosh S, May MJ, Kopp EB. NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol. 1998;16:225- 60.
  • 13. Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu Rev Immunol. 2000;18:621-63.
  • 14. Ghosh S, Karin M. Missing pieces in the NF-kappaB puzzle. Cell. 2002;109:81-96.
  • 15. Sen R, Baltimore D. Inducibility of kappa immunoglobulin enhancer-binding protein Nf-kappa B by a posttranslational mechanism. Cell. 1986;47:921-8.
  • 16. Luo JL, Kamata H, Karin M. IKK/NF-kappaB signaling: balancing life and death--a new approach to cancer therapy. J Clin Invest. 2005;115:2625-32.
  • 17. Sarkar FH, Li YW. Targeting multiple signal pathways by chemopreventive agents for cancer prevention and therapy. Acta Pharmacol Sin. 2007;28:1305-15.
  • 18. Sumitomo M, Tachibana M, Ozu C, Asakura H, Murai M, Hayakawa M et al. Induction of apoptosis of cytokine-producing bladder cancer cells by adenovirus-mediated IkappaBalpha overexpression. Hum Gene Ther. 1999;10:37-47.
  • 19. Sovak MA, Bellas RE, Kim DW, Zanieski GJ, Rogers AE, Traish AM et al. Aberrant nuclear factorkappaB/Rel expression and the pathogenesis of breast cancer. J Clin Invest. 1997;100:2952-60.
  • 20. Nakshatri H, Bhat-Nakshatri H, Martin DA, Goulet RJ, Sledge GW. Constitutive activation of NF-kappaB during progression of breast cancer to hormoneindependent growth. Mol Cell Biol. 1997;17:3629-39.
  • 21. Dejardin E, Deregowski V, Chapelier M, Jacops N, Gielen J, Merville MP et al. Regulation of NF-kappaB activity by I kappaB-related proteins in adenocarcinoma cells. Oncogene. 1999;18:2567-77.
  • 22. Bours V, Dejardin E, Goujon-Letawe F, Merville MP, Castronovo V. The NF-kappa B transcription factor and cancer: high expression of NF-kappa B- and I kappa B-related proteins in tumor cell lines. Biochem Pharmacol. 1994;47:145-9.
  • 23. Sumitomo M, Tachibana M, Nakashima J, Murai M, Miyajima A, Kimura F et al. An essential role for nuclear factor kappa B in preventing TNF-alphainduced cell death in prostate cancer cells. J Urol. 1999;161:674-9.
  • 24. Suh J, Payvandi F, Edelstein LC, Amenta PS, Zong WX, Gelinas C et al. Mechanisms of constitutive NFkappaB activation in human prostate cancer cells. Prostate. 2002;52:183-200.
  • 25. Herrmann JL, Beham AW, Sarkiss M, Chiao PJ, Rands MT, Bruckheimer EM et al. Bcl-2 suppresses apoptosis resulting from disruption of the NF-kappa B survival pathway. Exp Cell Res. 1997;237:101-9.
  • 26. Devalaraja MN, Wang DZ, Ballard DW, Richmond A. Elevated constitutive IkappaB kinase activity and IkappaB-alpha phosphorylation in Hs294T melanoma cells lead to increased basal MGSA/GRO-alpha transcription. Cancer Res. 1999;59:1372-7.
  • 27. Wang W, Abbruzzese JL, Evans DB, Larry L, Cleary KR, Chiao PJ. The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin Cancer Res. 1999;5:119-27.
  • 28. Sebens S, Arlt A, Schafer H. NF-kappaB as a molecular target in the therapy of pancreatic carcinoma. Recent Results Cancer Res. 2008;177:151- 64.
  • 29. Sclabas GM, Fujioka S, Schmidt C, Evans DB, Chiao PJ. NF-kappaB in pancreatic cancer. Int J Gastrointest Cancer, 2003;33:15-26.
  • 30. Dong QG, Sclabas GM, Fujioka S, Schmidt C, Peng B, Wu T et al. The function of multiple IkappaB : NFkappaB complexes in the resistance of cancer cells to Taxol-induced apoptosis. Oncogene. 2002;21:6510-9.
  • 31. Yeh PY, Chuang SE, Yeh KH, Song YC, Ea CK, Cheng AL. Increase of the resistance of human cervical carcinoma cells to cisplatin by inhibition of the MEK to ERK signaling pathway partly via enhancement of anticancer drug-induced NF kappa B activation. Biochem Pharmacol. 2002;63:1423-30.
  • 32. Mufson RA, Myers C, Turpin JA, Meltzer M. Phorbol ester reduces constitutive nuclear NF kappa B and inhibits HIV-1 production in mature human monocytic cells. J Leukoc Biol. 1992;52:637-44.
  • 33. Slater AF, Kimland M, Jiang SA, Orreneus S. Constitutive nuclear NF kappa B/rel DNA-binding activity of rat thymocytes is increased by stimuli that promote apoptosis, but not inhibited by pyrrolidine dithiocarbamate. Biochem J. 1995;312:833-8.
  • 34. Darieva ZA, Pospelov VA, Pospelova TV. Transcription factor NF-kappa B/RelA are constitutively activated and localized in the cell nuclei of E1A + cHa-Ras transformants. Tsitologiia. 1999;41:622-7.
  • 35. Wang W, Abbruzzese JL, Evans DB, Chiao PJ. Overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma is regulated by constitutively activated RelA. Oncogene. 1999;18:4554-63.
  • 36. Yang J, Richmond A. Constitutive IkappaB kinase activity correlates with nuclear factor-kappaB activation in human melanoma cells. Cancer Res. 2001;61:4901-9.
  • 37. Adsay NV, Basturk O, Bonnett M, Kilinc N, Andea AA, Feng J. A proposal for a new and more practical grading scheme for pancreatic ductal adenocarcinoma. Am J Surg Pathol. 2005;29:724-33.
  • 38. Hruban R, Boffetta P, Hiraoka N, IacobuzioDonahue C, Kato Y, Kern SE et al. Ductal adenocarcinoma of the pancreas, in Pathology and genetics of tumors of the digestive system. WHO classification of the tumors of the Digestive System.Eds F. Bosman, F. Carneiro, R. Hruban, N. Theise. 2010, IARC Press: Lyon. p.281-291.
  • 39. Blackbourne L, Jones R, Catalano C, Iezzoni J, Bourgeois F. Pancreatic adenocarcinoma in the pregnant patient: case report and review of the literature. Cancer. 1997;79:1776-9.
  • 40. Luttges J, Stigge C, Pacena M, Kloppel G. Rare ductal adenocarcinoma of the pancreas in patients younger than age 40 years. Cancer. 2004;100:173-82.
  • 41. Pernick N, Eldean Z, Kabbani W, Philip P, Shields A, Vaitkevicius V et al. Pancreatic ductal adenocarcinoma in young patients (abstract). Modern Pathology. 2001;14:201A.
  • 42. Evans D, Abruzzese J, Rich T.Cancer of the pancreas. In Textbook of Cancer: Principles and practice of oncology.(Eds V.T. Devita, S. Hellman, S.A. Rosenberg) 1126-1161. Lippincott-Raven ,MA, 2001.
  • 43. Brennan M, Moccia R, Klimstra D. Management of adenocarcinoma of the body and tail of the pancreas. Ann Surg. 1996; 223:506-11.
  • 44. Luttges J, Vogel I, Menke M, Henne-Bruns D, Kremer B, Kloppel G. The retroperitoneal resection margin and vessel involvement are important factors determining survival after pancreaticoduodenectomy for ductal adenocarcinoma of the head of the pancreas. Virchows Arch. 1998;433:237-42.
  • 45. Neoptolemos J, Stocken D, Friess H, Bassi C, Dunn J, Hickey H et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350:1200- 10.
  • 46. Nagakawa T, Nagamori M, Futakami F, Tsukioka Y, Kayahara M, Ohta T et a. Results of extensive surgery for pancreatic carcinoma. Cancer.1996;77:640-5.
  • 47. Trede M, Schwall G, Saeger H. Survival after pancreatoduodenectomy. 118 consecutive resections without an operative mortality. Ann Surg.1990; 211:447-58.
  • 48. Hruban RH, Goggins M, Parsons J, Kern SE. Progression model for pancreatic cancer. Clin Cancer Res, 2000;6:2969-72.
  • 49. Hruban RH, Wilentz RE, Kern SE. Genetic progression in the pancreatic ducts. Am J Pathol. 2000;156:1821-5.
  • 50. Mukhopadhyay T, Roth JA, Maxwell SA. Altered expression of the p50 subunit of the NF-kappa B transcription factor complex in non-small cell lung carcinoma. Oncogene. 1995;11:999-1003.
  • 51. Motokura T, Arnold A. PRAD1/cyclin D1 protooncogene: genomic organization, 5' DNA sequence, and sequence of a tumor-specific rearrangement breakpoint. Genes Chromosomes Cancer. 1993;7:89- 95.
  • 52. Visconti R, Cerutti J, Battista S, Fedele M, Trapasso F, Zeki K et al. Expression of the neoplastic phenotype by human thyroid carcinoma cell lines requires NFkappaB p65 protein expression. Oncogene. 1997;15:1987-94.
  • 53. Pham N, Schwock J, Iakovlev V, Pond G, Hedley D, Tsao M. Immunohistochemical analysis of changes in signaling pathway activation downstream of growth factor receptors in pancreatic duct cell carcinogenesis. BMC Cancer. 2008;8:43.
  • 54. Weichert W, Boehm M, Gekeler V, Bahra M, Langrehr J, Neuhaus P et al. High expression of RelA/p65 is associated with activation of nuclear factor-kappaB-dependent signaling in pancreatic cancer and marks a patient population with poor prognosis. Br J Cancer. 2007;97:523-30.
  • 55. Burris H, Storniolo A. Assessing clinical benefit in the treatment of pancreas cancer: gemcitabine compared to 5-fluorouracil. Eur J Cancer. 1997;33:18-22.
  • 56. Burris H, Moore M, Andersen J, Green M, Rothenberg M, Modiano M et al. Improvements in survival and clinical benefit with gemcitabine as firstline therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403-13.
  • 57. Arlt A, Gehrz A, Muerkoster S, Vorndamm J, Kruse M, Folsch U et al. Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. Oncogene. 2003;22:3243-51.
  • 58. Chandler N, Canete J, Callery M. Increased expression of NF-kappa B subunits in human pancreatic cancer cells. J Surg Res. 2004;118:9-14.
  • 59. Li L, Braiteh F, Kurzrock R. Liposome-encapsulated curcumin: in vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis. Cancer. 2005;104:1322-31.
  • 60. Dhillon N, Aggarwal BB, Newman RA, Wolff RA, Kunnumakkara AB, Abbruzzese JL et al. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res. 2008;14:4491-9.
Cukurova Medical Journal-Cover
  • ISSN: 2602-3032
  • Yayın Aralığı: Yılda 4 Sayı
  • Başlangıç: 1976
  • Yayıncı: Çukurova Üniversitesi Tıp Fakültesi
Sayıdaki Diğer Makaleler

Evre 3-4 vajinal cuff prolapsusu tedavisinde konvansiyonel enstrümanlar kullanılarak sakrospinöz ligament fiksasyon sonuçları

Hanifi ŞAHİN, İbrahim YALÇIN, Eda Adeviye ŞAHİN, Mustafa Erkan SARI, Ali AYHAN

Fetus kadavralarında parotid bez içerisindeki fasiyal sinirin terminal dallarının morfolojik değerlendirilmesi

Canan ERTEMOĞLU ÖKSÜZ, Ahmet KALAYCIOĞLU, Özlem UZUN, Şahi Nur KALKIŞIM

Klorzoksazon’un antibakteriyel etkisinin belirlenmesi

Mostafa Norizadeh Tazehkand

Pankreas duktal adenokarsinomunda NF-Kappa B ekspresyonu

Deniz TUNÇEL, N. Ümit BAYOL

Klorzoksazonun antibakteriyel etkisinin belirlenmesi

Mostafa NORİZADEH TAZEHKAND, Mehmet Bertan YILMAZ

Hemşirelik öğrencilerinin şiddet eğilimlerinin belirlenmesi

İpek KÖSE TOSUNÖZ, Gürsel ÖZTUNÇ, Zehra ESKİMEZ, Pınar YEŞİL DEMİRCİ

Huntington hastalığı tanısı almış hastalarda ve ailelerinde CAG trinükleotid tekrar sayılarının fragman analizi ile tespiti

Davut ALPTEKİN, Perçin PAZARCI, Mehmet Ali BEREKETOĞLU, Mehmet Ali ERKOÇ, Nermin Seda ILGAZ, Ümit LÜLEYAP

Üniversite öğrencilerinin ilişkilerle ilgili bilişsel çarpıtmaları ve öfke ifade tarzları

Arzu YÜKSEL, Emel BAHADIR YILMAZ

Psoriazisin klinik şiddeti ile histopatolojik bulgular arasında ilişki var mıdır? klinikopatolojik bir çalışma

Figen ASLAN

Ebelik öğrencilerinin sosyal zeka düzeyleri ile meslek algıları arasındaki ilişki

Emine AKÇA, Şule GÖKYILDIZ SÜRÜCÜ, Meltem AKBAŞ, Ayşe ŞENOĞLU